Aktiesnakken — September 2013
-
http://medwatch.dk/Medicinal___Biotek/article5993606.ece ADC anbefalet fra Roche
-
Ligner dog en større Nordea kunde der sælger nu, Novod må lige få rettet op
-
Nordea for satan !
-
Novod må undersøge hvem der sælger og så lige gribe knoglen og tale dem til fornuft
-
jeg tror ikke vi skal vente særligt længe
-
tror jeg heller ikke aka
Dara ruller ud nu -
Jeg er stadig ikke overbevist om den short. Deutsche virker ikke desperate og intet er meldt til Finantilsynet
-
“The perception of Arzerra is now shifting,” Bowers, who’s based in Copenhagen, said by phone. “The view of Arzerra is changing from a product that the market didn’t rate as highly as GA101, to a product rated on the same level or perhaps even higher.”
-
nej det er mere en fornemmelse
-
og de plejer at være meget gode
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind